Skip to main content
Clinical Trials/NCT04202367
NCT04202367CompletedNot Applicable

Transversus Abdominis Plane (TAP) Block With Different Bupivacaine Concentrations in Pediatric Patients Undergoing Unilateral Inguinal Hernia Repair Surgery: A Prospective Randomised Double-Blinded Study

Istanbul University0 sites74 target enrollmentStarted: November 1, 2016Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
74
Primary Endpoint
FLACC pediatric pain scores

Study Overview

Brief Summary

This study is designed to compare the analgesic efficacy of different bupivacaine concentrations in pediatric patients undergoing ultrasound-guided transversus abdominis plane (TAP) block for unilateral inguinal hernia repair. In recruited 74 patients; Group 1 (n:37) received 1 mg/kg bupivakain 0.25% and Group 2 (n: 37) received 1 mg/kg bupivakain 0.125% for ultrasound-guided TAP block following standard general anaesthesia induction. FLACC (Face, Legs, Activity, Cry, Consolability) behavioral pain assessment scale was used for evaluating patients' postoperative pain levels at 15-, 30-, 45-minute and 1-, 2-, 6-, 24-hour. Tramadol 1 mg/kg was administered intravenously as rescue analgesic when FLACC score was ≥4. Total analgesic requirement, length of hospital stay and side effects were recorded.

Detailed Description

Transversus abdominis plane (TAP) block is a safe and effective analgesia technique for paediatric patients. This study is designed to compare the analgesic efficacy of different bupivacaine concentrations in paediatric patients undergoing ultrasound-guided TAP blocks for unilateral inguinal hernia repair surgery. Seventy-four patients aging between 1 and 8 years, undergoing unilateral inguinal hernia surgery, were enrolled for this study after obtaining Institutional Ethics Committee approval and written informed consents from parents or legal guardians (2016/1281). Group 1 (n:37) received 1 mg/kg bupivakain 0.25% and Group 2 (n: 37) received 1 mg/kg bupivakain 0.125% for ultrasound-guided TAP block following standard general anaesthesia induction. All patients received remifentanil 0,1 μg/kg/h infusion and paracetamol 15 mg/kg intraoperatively, and paracetamol 4x15 mg/kg per day postoperatively. FLACC (Face, Legs, Activity, Cry, Consolability) behavioral pain assessment scale was used for evaluating patients' postoperative pain levels at 15-, 30-, 45-minute and 1-, 2-, 6-, 24-hour. Tramadol 1 mg/kg was administered intravenously as rescue analgesic when FLACC score was ≥4. Total analgesic requirement, length of hospital stay and side effects were recorded.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Masking Description

Seventy-four patients aging between 1 and 8 years, undergoing unilateral inguinal hernia surgery, were enrolled in the study and were randomized using closed envelope method.

Eligibility Criteria

Ages
1 Year to 8 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • American Society of Anesthesiologists (ASA) status I/II
  • Children between 1 to 8 years of age
  • Patients undergoing unilateral inguinal hernia repair surgery

Exclusion Criteria

  • Denial of parents
  • Patients who are allergic to local anesthetics

Arms & Interventions

TAP block with 1 mg.kg-1 bupivacaine 0.25%

Active Comparator

Patients had 1 mg.kg-1 bupivacaine 0.25% with US-guided TAP block

Intervention: 1 mg.kg-1 bupivacaine 0.25% (Drug)

TAP block with 1 mg.kg-1 bupivacaine 0.125%

Active Comparator

Patients had 1 mg.kg-1 bupivacaine 0.125% with US-guided TAP block

Intervention: 1 mg.kg-1 bupivacaine 0.125% (Drug)

Outcomes

Primary Outcomes

FLACC pediatric pain scores

Time Frame: up to 24 hours

It corporates five categories of behavior, each scored on 0-2 point scale so that total score ranges from 0-10.

Secondary Outcomes

  • Total analgesic requirement(up to 24 hours)
  • First analgesic requirement time(up to 24 hours)
  • Incidence of side effects(up to 24 hours)
  • The length of hospital stay(up to 24 hours)
  • Incidence of complications(up to first week.)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Meltem Savran Karadeniz

Associate Professor

Istanbul University

Similar Trials